Infantile Spasms in Tuberous Sclerosis When Hormonal Therapy Has Not Stopped Spasms
Clinical scenario
This protocol addresses infantile spasms occurring in a patient with an established diagnosis of tuberous sclerosis. This population has distinct treatment considerations: patients with tuberous sclerosis are more likely to respond to certain treatments than infants without an identified etiology, and treatment selection reflects those differences.
Previous treatment did not achieve goals
The prior step — switching to a different first-line hormonal agent (ACTH or prednisolone) — failed to achieve complete cessation of spasms and resolution of hypsarrhythmia on video EEG, typically assessed within 14 days. This unmet endpoint triggers escalation to the next treatment line.
Next-line approach (partial overview)
When first-line hormonal therapy has not produced the required outcome in this setting, further management may involve dietary therapy — such as the ketogenic diet — or alternative antiepileptic strategies. The complete regimen, selection criteria, and sequencing are available in the full protocol.
Treatment goal:
Complete cessation of spasms. Spasm freedom has been reported within 1–3 months.
References
DOI: 10.3978/j.issn.2224-4336.2015.09.01
- For example, patients with tuberous sclerosis are more likely to respond to treatment with vigabatrin, whereas patients without an identified etiology may respond better to hormonal therapy.
- Vigabatrin is the preferred first-line therapy for patients with infantile spasms and tuberous sclerosis, with some studies showing efficacy of greater than 90% in patients with tuberous sclerosis.
- Many other treatment options continue to be explored, including the ketogenic diet, traditional anti-epileptic medications, and resective surgery in select cases.
- Diet ratio ranged from 3 : 1 to 4 : 1.
- The goal of treatment of infantile spasms remains complete cessation of spasms.
- Spasm freedom has been reported in 14-65% of patients within 1-3 months.
View source ↗